Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib Monotherapy for Bone Metastases in Advanced Renal Cell Carcinoma (Japan)
jRCTs031210220Completed
- Sponsor
- Takeda
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cabozantinib in clear cell renal cell carcinoma (ccRCC) and bone metastases, sponsored by Takeda. Primary endpoint: Objective response rate of bone target lesions (MDA criteria, IRC-assessed). Started Sep 2021; status: completed.
02
Drugs
cabozantinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)bone metastases
Beyond the preview
Go deeper on jRCTs031210220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210220.